Hikma Pharmaceuticals (LON:HIK) Stock Passes Below 200 Day Moving Average - Here's Why

Key Points

• Price breach of 200‑day MA: Hikma's shares slipped below the 200‑day moving average of GBX 1,520.39, trading as low as GBX 1,311 and last at GBX 1,402.50 on volume of 1,460,338 shares.
• Analysts remain bullish: Five analysts rate the stock a "Buy" with a consensus price target of GBX 2,326; Berenberg raised its target to GBX 2,300 while Deutsche Bank trimmed its target to GBX 2,400, both keeping Buy ratings.
• Valuation and leverage snapshot: Market cap is £3.03 billion with a P/E of 7.75 and P/E/G of 2.38, and the company shows moderate leverage (debt-to-equity 63.59) with current liquidity (current ratio 1.82).

Hikma Pharmaceuticals PLC (LON:HIK - Get Free Report)'s share price crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of GBX 1,520.39 and traded as low as GBX 1,311. Hikma Pharmaceuticals shares last traded at GBX 1,402.50, with a volume of 1,460,338 shares traded.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Berenberg Bank upped their price target on Hikma Pharmaceuticals from GBX 1,800 to GBX 2,300 and gave the stock a "buy" rating in a report on Wednesday, March 4th. Deutsche Bank Aktiengesellschaft decreased their price target on Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a "buy" rating for the company in a report on Friday, January 9th. Five research analysts have rated the stock with a Buy rating, According to MarketBeat, Hikma Pharmaceuticals presently has a consensus rating of "Buy" and an average price target of GBX 2,326.

Hikma Pharmaceuticals Price Performance

The stock has a market cap of £3.03 billion, a P/E ratio of 7.75, a P/E/G ratio of 2.38 and a beta of 0.61. The company has a debt-to-equity ratio of 63.59, a quick ratio of 1.27 and a current ratio of 1.82. The business has a 50 day simple moving average of GBX 1,343.34 and a 200-day simple moving average of GBX 1,520.39.

About Hikma Pharmaceuticals

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.